Likewise, monoclonal antibodies directed against CD133 protein induced a specific dose-dependent cytotoxic effect in metastatic melanoma cells, suggesting CD133 as a potential target for immunotherapy [11]. This evidence concerns the gene PROM1 and metastatic melanoma.